Pharmaceutical industry

Results: 25564



#Item
31BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

Add to Reading List

Source URL: www.harvard-jlpp.com

Language: English
32The Continuous Quality Improvement (CQI) unit (“CQI Team”) is responsible for designing, implementing and maintaining a program

The Continuous Quality Improvement (CQI) unit (“CQI Team”) is responsible for designing, implementing and maintaining a program

Add to Reading List

Source URL: humansubjects.stanford.edu

Language: English - Date: 2016-04-12 01:21:48
33Pharmaceuticals and Medical Devices Safety Information No. 334 June 2016

Pharmaceuticals and Medical Devices Safety Information No. 334 June 2016

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2016-08-03 04:15:08
34Food and Drug Administration, HHS  § 50.3 PART 50—PROTECTION OF HUMAN SUBJECTS

Food and Drug Administration, HHS § 50.3 PART 50—PROTECTION OF HUMAN SUBJECTS

Add to Reading List

Source URL: publicfiles.jaeb.org

Language: English - Date: 2014-01-30 11:37:23
35BPGWorksharingEMA-CMDv

BPGWorksharingEMA-CMDv

Add to Reading List

Source URL: www.hma.eu

Language: English - Date: 2016-07-07 08:05:52
36Microsoft Word - SOP editedonlineversibaru.doc

Microsoft Word - SOP editedonlineversibaru.doc

Add to Reading List

Source URL: www.ummc.edu.my

Language: English - Date: 2015-06-03 21:28:52
37Return Goods Policy Non-Returnable Products: Once these prescription products are removed from our internal Supply Chain control, product must be destroyed if returned, in accordance with the specifications mandated by t

Return Goods Policy Non-Returnable Products: Once these prescription products are removed from our internal Supply Chain control, product must be destroyed if returned, in accordance with the specifications mandated by t

Add to Reading List

Source URL: www.sigmatau.com

Language: English - Date: 2015-07-06 14:50:13
38CMDh meeting with representative of Interested Parties 19 May 2015  Type IA variation label implementation guidance.

CMDh meeting with representative of Interested Parties 19 May 2015  Type IA variation label implementation guidance.

Add to Reading List

Source URL: www.hma.eu

Language: English - Date: 2015-05-29 10:18:53
39PRESS RELEASE  Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration  Collaboration is based on Oncodesign’s Nanocyclix® technology

PRESS RELEASE Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration  Collaboration is based on Oncodesign’s Nanocyclix® technology

Add to Reading List

Source URL: www.oncodesign.com

Language: English - Date: 2016-01-04 13:50:16
40Pharmaceutical industry / Medical research / Clinical data management / Clinical research / Health care / Evaluation / Validity / Quality / Validation / Marketing authorization / Electronic submission

Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions <> "Error*"Annex VI: Implementation of mandatory VNeeS format for Veterinary regulatory submissions \* MERGEFORMAT Annex VI: Imple

Add to Reading List

Source URL: esubmission.ema.europa.eu

Language: English - Date: 2016-08-19 03:16:08